---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000066"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:40:50.565561+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma discontinues Phase 2 migraine study after failed endpoints; CFO terminated, CEO takes PFO role

## Summary
- Phase 2 double-blind migraine study (episodic and chronic cohorts) discontinued; chronic cohort failed primary and secondary endpoints.
- Open-label extension study also stopped; patients monitored for safety for 12 weeks post last treatment.
- CEO Marc Forth appointed principal financial officer after termination of CFO Peter Reynolds effective May 17, 2024.
- Jennifer Sy appointed principal accounting officer; no additional compensation for Forth or Sy.
- Company to conserve cash and evaluate strategic options after study discontinuation.

## SEC filing metadata
- accession: 0001837607-24-000066
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000066/0001837607-24-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000066/aeon-20240516x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000066
- JSON: https://secwatch.observer/filing/0001837607-24-000066.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000066.txt

## Key facts
- Executive change
  Peter Reynolds was terminated as Chief Financial Officer at AEON Biopharma, Inc..
  - Action: terminated
  - Role: Chief Financial Officer
  source text: On May 16, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) terminated the Consulting Agreement (the “Agreement”) between AEON and Peter Reynolds, which has resulted in his termination as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company effective as of May 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000066/0001837607-24-000066-index.htm
- Executive change
  Marc Forth was appointed as principal financial officer at AEON Biopharma, Inc..
  - Action: appointed
  - Role: principal financial officer
  source text: On May 16, 2024, our Board of Directors appointed Marc Forth, age 53, as our principal financial officer, effective as of May 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000066/0001837607-24-000066-index.htm
- Executive change
  Jennifer Sy was appointed as principal accounting officer at AEON Biopharma, Inc..
  - Action: appointed
  - Role: principal accounting officer
  source text: On May 16, 2024, our Board of Directors appointed Jennifer Sy, age 39, as our principal accounting officer, effective as of May 17, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000066/0001837607-24-000066-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.